Problem

Obstructive Sleep Apnea:
Currently **1 billion** people suffer from obstructive sleep apnea (OSA) globally, and only **20%** of them are clinically diagnosed. Amongst the **200 million** people who were diagnosed with OSA, an astonishing **60%** of them suffered from one or more of these chronic disorders:

- Diabetes
- Obesity
- Heart attack
- Stroke
- Alzheimer’s
- Depression
- Cancer
- ADHD
- High Blood Pressure
- Impotence
- Congestive Heart Failure
- Metabolic Syndrome

Solution

ApnoMed has developed a revolutionary patented, and FDA cleared oral sleep device which is one of the most effective sleep devices on the market at managing **moderate to severe** obstructive sleep apnea (OSA) with no long-term side effects. Unlike other solutions that force the lower jaw forward in an unnatural way, ApnoMed’s proprietary mechanism gently guides the lower jaw forward to the ideal natural resting posture, eliminating all long-term side effects such as, TMJ pain, permanent tooth movement and permanent bite change. This unique device has allowed ApnoMed to have a success rate of **90%** in over **385 patients** for fully resolving all OSA symptoms.

Market Opportunity

The US sleep apnea device market was valued at 4.33 Billion in 2018 and expected to reach 9.10 Billion by 2025 with a CAGR of **11.20%** over the forecasted period. The key factors leading to such a high valued market can be attributed to the rising prevalence of OSA and respiratory disorders, in addition to the presence of highly unmet medical needs addressing OSA in emerging foreign economies. Currently only **20%** of the **1 billion** people suffering from OSA are clinically diagnosed, which leaves an untouched market of **800 million** people that are undiagnosed and will need some sort of intervention.